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Introduction
A 9-year-old with cerebral palsy 
received an injection of the neurotoxin 
“Botox” to relieve muscle spasms. 
This off-label use was legal but 
not approved by the US Food and 
Drug Administration (FDA) for this 
indication. People with headaches 
have also received Botox injections as 
a legal, but unapproved, treatment—in 
this case the FDA is investigating 
whether the manufacturer actually 
promoted the drug for this indication. 
In fact, the drug has some significant 
dangers leading to hospitalizations and 
deaths [1].
A more familiar instance of off-
label drug use would be the example 
of a 47-year-old male presenting to 
his doctor with lower back pain. The 
doctor, having previously suggested 
over-the-counter medications, 
prescribes a drug to ease the pain. The 
doctor tells the patient to take the drug 
three times a day, but provides no other 
information. In this case, a reasonable 
person might wish to be told: (1) that 
the prescribed drug gabapentin was 
approved by the FDA only to treat 
seizures in epilepsy—not for back 
pain; and (2) that no reliable research 
supports using the drug for back pain. 
These examples are not uncommon, 
yet current practice does not require 
or even suggest that doctors disclose 
any of these facts to their patients. This 
article argues that as an extension of 
the legal doctrine of informed consent 
and the ethical duty of shared decision-
making (SDM), patients should be told 
when a drug is being prescribed “off-
label;” that is, it has not been approved 
for the indication and is being used 
experimentally.  
Off-Label Prescribing 
Because a basic premise of the US 
Federal Food, Drug, and Cosmetic 
Act is that manufacturers are 
prohibited from marketing drugs or 
devices without FDA approval, the 
public commonly assumes that all 
uses of prescription drugs have been 
approved by the FDA. However, after 
a drug is approved for one set of 
indications, researchers and doctors 
often discover new applications for 
it. Even when the FDA approves a 
drug for a single, specific use, doctors 
may legally prescribe the drug to any 
patient for any use. Physicians are 
not restricted to prescriptions that 
comply with the FDA approval. The 
FDA considers such treatments “off-
label” because substantial evidence 
regarding their safety and efficacy has 
not been presented or evaluated. But 
such uses are perfectly legal. In fact, 
FDA policy explicitly states that “once 
a [pharmaceutical] product has been 
approved for marketing, a physician 
may prescribe it for uses in treatment 
regimes of patient populations that are 
not included in the approved labeling” 
[2]. Indeed, as the Supreme Court has 
recognized, off-label prescribing “is an 
accepted and necessary corollary of the 
FDA’s mission to regulate in this area 
without directly interfering with the 
practice of medicine” [3].
There are many examples of 
responsible, off-label prescribing. 
Specifically, pediatric prescriptions 
are frequently off-label because many 
drugs have not been tested on children. 
Aspirin was widely prescribed to reduce 
the risk of heart attack long before it 
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Summary Points 
s  Off-label prescriptions are those that 
do not comply with the FDA-approved 
use for the drug. While they are legal 
and account for roughly half of all 
prescriptions written today, often they 
are not supported by sound scientific 
evidence. 
s  In addition, they have the potential to 
drive up the cost of health care and 
expose patients to unnecessary risks 
and uncertain outcomes. Legal and 
ethical principles require physicians to 
inform patients about risks of medical 
treatments. 
s  We propose that the doctrine of 
informed consent be rigorously 
applied to require doctors to disclose 
to patients when they are prescribing 
a drug off-label. 
s  Providing full disclosure to patients 
and encouraging them to share 
in decision-making in situations 
of medical uncertainty is vital to 
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was FDA-approved for this purpose. 
Off-label uses are widespread in 
oncology, and off-label, antiretroviral 
combination therapies have saved 
many AIDS patients. In short, off-label 
drug prescribing is a significant part of 
mainstream medicine [4].
While off-label prescriptions are 
common and sometimes necessary, 
they also present significant risks. 
Often, the drug has not been proven 
safe or effective for treating the 
patient’s condition [5,6], and off-label 
prescribing usually “occurs without 
scientific support” [6]. FDA panels 
have found that off-label uses can be 
dangerous [7,8]. For example, doctors 
wrote 18 million prescriptions for 
the off-label use of fenfluramine for 
weight loss before it was discovered 
that thousands of people suffered heart 
valve damage from it [7].
 Off-label prescribing has potential 
consequences for both the individual 
patient and for our health care system. 
First, an off-label prescription may be 
ineffective or downright detrimental 
in treating the medical condition. By 
definition, no governmental body has 
evaluated the effectiveness or safety 
for the off-label indication, and often 
there is no rigorous evidence base to 
properly evaluate the drug. Second, 
accepting poorly studied therapies 
heightens the risk of overmedication 
and drug interactions. And finally, the 
drugs prescribed off-label are often 
more expensive than an off-patent or 
generic medicine. 
Furthermore, there is the potential 
for an escalating financial burden on 
our health care system. According to a 
report by the National Association of 
Attorneys General, the single biggest 
factor driving the increase in health 
care costs is the price of prescription 
drugs [9,10]. It is likely that a significant 
part of prescription drug cost is due 
to increased off-label prescribing of 
on-patent drugs [11,12]. Prescription 
drugs are the fastest growing part of our 
health care costs [9,10], with spending 
increasing at double-digit rates annually 
from 1997 to 2005 [9]. Between 
1990 and 2002, the amount spent on 
prescription drugs in the United States 
increased 4-fold from US$40.6 billion to 
US$162 billion [9].
In practice, the FDA exercises little 
oversight on off-label promotion. 
Making matters worse, pharmaceutical 
companies often publish questionable 
research using medical education and 
communication companies (MECCs) 
[10]. These MECCs conduct flimsy 
research and present continuing 
medical education courses on off-label 
uses [10]. Often research is written by 
company-paid ghost writers but bears 
the name of a medical school faculty 
member paid generously for the use 
of their name [13,14]. These “articles” 
are then presented to doctors at free 
“educational” programs [10,15]. This 
strategy is often used to promote off-
label, on-patent uses. Not surprisingly, 
these studies are heavily biased in 
favor of the company’s product 
and aggressively disseminated to 
practicing physicians using the army of 
pharmaceutical sales representatives. 
Unfortunately, lax regulation has 
sometimes led to illegal over-promotion 
of off-label therapies. 
Informed Consent, Shared 
Decision-Making, and Off-Label 
Prescriptions 
Given that off-label prescribing of drugs 
may expose patients to unnecessary 
risks and may result in the prescribing 
of expensive new drugs when older 
ones are equally effective, cheaper, 
and safer, it is reasonable to apply the 
ethical mandate for SDM to doctors 
and require that health care providers 
disclose off-label prescribing to patients 
and seek their consent to the off-label 
use. In the US there are two grounds 
for requiring these discussions, one 
legal (informed consent) and one 
ethical (SDM). 
A. The legal doctrine of informed 
consent. While laws and policies in 
other countries may differ, in the 
US today, legal standards require 
physicians to obtain informed consent 
from a person before performing a test 
or starting a treatment—particularly 
a treatment that involves some 
uncertainty [16]. The doctrine of 
informed consent reflects the value we 
place on patient autonomy. Until the 
early twentieth century, doctors were 
not required to inform their patients of 
the risks and alternatives to a proposed 
treatment. The assumption was that 
doctors knew what was best for patients 
and that patients were sufficiently 
protected by their doctors’ interest in 
their well-being. Over time, as patients 
asserted greater autonomy rights, the 
law evolved to impose a duty on doctors 
to make “those disclosures which 
a reasonable medical practitioner 
would make under the same or similar 
circumstances”  [17]. Some later cases 
took patient autonomy a step further 
by refocusing the analysis on the 
information the patient would want to 
know rather than on the information a 
doctor would customarily disclose [18]. 
According to the doctrine of informed 
consent, the doctor is required to 
disclose the nature of an intervention, 
pros and cons of intervention, 
alternatives to intervention, and pros 
and cons of alternatives. This is where 
the informed-consent doctrine stands 
today: some states use the reasonable-
doctor standard while others use the 
reasonable-patient standard. Under 
either approach, the law recognizes 
a “therapeutic privilege” when full 
disclosure would be detrimental to a 
patient’s total care and best interests. 
Given that patients assume a drug 
prescribed by their doctor (1) has 
been proven safe and effective, (2) is 
FDA approved, and (3) is supported 
by scientific evidence [6], the question 
becomes: should an off-label therapy 
be disclosed to satisfy the requirements 
of informed consent? Would this 
information likely affect a patient’s 
decision to take the medicine [19]? 
In other words, are these risks that a 
reasonable person might wish to know 
about before accepting a prescription? 
If so, then requiring disclosure makes 
sense. It is important to note that FDA 
approval is not a panacea, nor does 
FDA approval guarantee safety and 
effectiveness (e.g., Vioxx and ezetimibe 
are just two recent examples of drugs 
approved by the FDA that turned out 
to pose dangers to users). Despite these 
problems, FDA approval is one step 
better than no approval. Of course, 
disclosure would absolutely be required 
Box 1. Characteristics of 
Decisions that Lend Themselves 
Best to Shared Decision-Making
s  Decisions where the effectiveness of 
the outcome is uncertain;
s  Decisions where the risks and benefits 
are sizeable or nearly equal;
s  Decisions where the patient is able and 
willing to participate; and
s  Decisions where the patient can 
understand the trade-offs between 
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if the patient was involved in a formal 
drug research trial. In many ways the 
patient given an off-label prescription 
is involved in an “n of one” research 
trial and should be required to provide 
informed consent. 
To date, no court has required a 
doctor to disclose that a therapy is 
off-label. In the few cases considering 
the issue, the courts have concluded 
that FDA classifications “do not 
speak directly to the medical issues” 
[20]. Those who oppose a disclosure 
requirement argue that disclosure 
would unduly frighten patients who 
would then refuse optimal treatments 
[21,22]. They have also claimed that 
requiring disclosure would unduly 
burden doctors whose attention 
would be diverted away from patient 
care, as they would be forced to read 
government materials to determine the 
risks, benefits, and approval status of 
each drug [9].
These concerns are minor 
and theoretical compared to the 
real imperative of patient self-
determination. Does concern 
about frightening patients preclude 
discussion about surgery or other 
medical treatments? The notion that 
patients cannot make competent 
health care decisions when provided 
truthful information flies in the face 
of the values supporting the doctrine 
of informed consent. Further, in the 
exceptional case where disclosure 
would be detrimental to the patient’s 
health, the therapeutic privilege 
already allows a doctor to withhold the 
information. Rather than routinely 
withholding this information from 
competent patients, doctors should 
be required to routinely disclose it to 
promote patient autonomy, ensure 
informed consent, and engage in SDM.
Moreover, determining approval 
status is hardly an undue burden. 
It is a simple task to determine the 
FDA status of a drug and approved 
indications. The information is readily 
available in the approved product 
label, the Physicians’ Desk Reference, 
and on-line services. Since 2006, the 
FDA has required drug manufacturers 
to provide the FDA-approved uses 
in a computer format that is readily 
accessible to doctors’ computers and 
hand-held devices, and this information 
is a part of some electronic medical 
records systems [23]. In addition, the 
FDA is standardizing and simplifying 
the approval information to make 
it even more readily available and 
understandable [9]. Increasingly 
expert medical opinion supports the 
feasibility of disclosing off-label uses. 
Specifically, in 2006, a multidisciplinary 
group developed a policy for off-label 
prescribing for medical centers [24]. 
It concluded that for off-label uses—
where the prescribing is not sufficiently 
tested to allay concerns about safety, 
efficacy, and cost-effectiveness—
“physicians . . . must meet their ethical 
obligations by ensuring that the patient 
is informed and provides consent prior 
to administering the drug” [9,16,25]. 
One insurance company already 
provides a form for physicians to use 
in obtaining informed consent for off-
label uses [26]. So, it appears that off-
label disclosure is practically feasible. 
B. The ethical requirement of SDM. 
The ethical requirement for SDM goes 
even further than the legal doctrine of 
informed consent. Initially, SDM involves 
a discussion to determine a patient’s 
desire to participate in decision-making. 
It then involves a presentation of 
information about reasonable options in 
terms patients can understand. Finally, 
it involves both the doctor and the 
patient arriving at a mutually acceptable 
decision based on their shared 
knowledge and values. Characteristics 
of decisions that lend themselves best to 
SDM are outlined in Box 1.
Off-label prescribing seems the 
poster child for SDM, where some 
indications suggest a benefit but others 
suggest known and unknown risks—in 
other words, medical uncertainty. 
Faced with medical uncertainty, doctors 
owe patients the ethical duty to inform 
them of the uncertainty and offer them 
choices. It’s one thing to prescribe a 
drug off-label for a serious condition 
when there are no other FDA-approved 
therapies, especially when reliable 
research supports the prescription. It is 
quite another to prescribe a drug off-
label when there are safe and effective 
FDA-approved alternatives or when the 
patient’s condition is not sufficiently 
serious to warrant the risks of an 
unproven and potentially dangerous 
treatment. However, from an ethical 
perspective, both cases require open, 
honest discussions where doctors tell 
their patients that the use of the drug 
will be off-label and thus not approved 
for this indication, explain the risks, 
potential benefits, and alternatives, and 
then ask patients for their permission 
to proceed.
At a minimum, physicians should be 
required to include the items in Box 
2 in discussions and document that 
they have engaged patients in a SDM 
process.
Conclusion
Patients need information about 
off-label uses to make well-informed 
health care decisions. The legal 
doctrine of informed consent should 
be expanded to require disclosure of 
off-label prescribing where the drug 
has not been proven safe and effective 
for the condition, especially where 
scientific evidence is inadequate and 
risks are substantial or unknown. The 
ethical requirement of SDM should 
be expanded to require discussions 
of off-label uses under the same 
circumstances. Requiring disclosure 
will protect patient autonomy and 
educate patients about alternatives and 
risks, leading to improved health care 
decisions.  
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